UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Journal of translational medicine, 2010-07, Vol.8 (1), p.71-71, Article 71

2010

Volltextzugriff (PDF)

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-11, Vol.15 (12), p.1351-1360

2014

Volltextzugriff (PDF)

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

The lancet oncology, 2013-09, Vol.14 (10), p.962-970

2013

Volltextzugriff (PDF)

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies

PloS one, 2020-01, Vol.15 (1), p.e0227356-e0227356

2020

Volltextzugriff (PDF)

Pertuzumab and trastuzumab: the rationale way to synergy

Anais da Academia Brasileira de Ciências, 2016-01, Vol.88 Suppl 1 (suppl 1), p.565-577

2016

Volltextzugriff (PDF)

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Journal of clinical oncology, 2007-07, Vol.25 (19), p.2678-2684

2007

Volltextzugriff (PDF)

Looking for predictive markers in breast cancer – Authors' reply

The lancet oncology, 2015, Vol.16 (1), p.e1-e2

Gligorov, Joseph

2015

Volltextzugriff (PDF)

Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC

Nature reviews. Clinical oncology, 2015-09, Vol.12 (9), p.508-509

2015

Volltextzugriff (PDF)

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Volltextzugriff (PDF)

Simultaneous quantification of four hormone therapy drugs by LC-MS/MS: Clinical applications in breast cancer patients

Journal of pharmaceutical and biomedical analysis, 2024-05, Vol.242, p.116032-116032, Article 116032

2024

Volltextzugriff (PDF)

Does Concurrent Radiochemotherapy Affect Cosmetic Results in the Adjuvant Setting After Breast-Conserving Surgery? Results of the ARCOSEIN Multicenter, Phase III Study: Patients’ and Doctors’ Views

International journal of radiation oncology, biology, physics, 2007-05, Vol.68 (1), p.66-72

2007

Volltextzugriff (PDF)

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer

European journal of cancer (1990), 2016-10, Vol.66, p.104-113

2016

Volltextzugriff (PDF)

Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective

Breast (Edinburgh), 2017-04, Vol.32, p.247-255

2017

Volltextzugriff (PDF)

Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer

Cancer, 2008-09, Vol.113 (6), p.1294-1301

2008

Volltextzugriff (PDF)

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

Clinical cancer research, 2018-07, Vol.24 (13), p.3053-3058

2018

Volltextzugriff (PDF)

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First‐Line Treatment for HER‐2‐positive Locally Recurrent or Metastatic Breast Cancer

The oncologist (Dayton, Ohio), 2012-04, Vol.17 (4), p.469-475

2012

Volltextzugriff (PDF)

Prospective Clinical Utility Study of the Use of the 21‐Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor‐Positive Early Invasive Breast Cancer: Results From the SWITCH Study

The oncologist (Dayton, Ohio), 2015-08, Vol.20 (8), p.873-879

2015

Volltextzugriff (PDF)

The emerging role of aromatase inhibitors in the adjuvant management of breast cancer

Reviews on recent clinical trials, 2006-09, Vol.1 (3), p.237-249

2006

Volltextzugriff (PDF)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Breast cancer research and treatment, 2013-10, Vol.141 (3), p.437-446

2013

Volltextzugriff (PDF)

Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial

Breast (Edinburgh), 2017-08, Vol.34, p.89-95

2017

Volltextzugriff (PDF)

COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence, in collaboration with the Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), the Société d'Imagerie de la Femme (SIFEM), the Société Française de Chirurgie Oncologique (SFCO), the Société Française de Sénologie et Pathologie Mammaire (SFSPM) and the French Breast Cancer Intergroup-UNICANCER (UCBG)

Bulletin du cancer, 2020-05, Vol.107 (5), p.528

2020

Volltextzugriff (PDF)

Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic

European journal of medical genetics, 2020-12, Vol.63 (12), p.104098-104098, Article 104098

2020

Volltextzugriff (PDF)

Concurrent trastuzumab – Internal mammary irradiation for HER2 positive breast cancer: “It hurts to be on the cutting edge”

Radiotherapy and oncology, 2010-01, Vol.94 (1), p.119-120

2010

Volltextzugriff (PDF)

Incidence, risk factors, and outcomes of central venous catheter‐related thromboembolism in breast cancer patients: the CAVECCAS study

Cancer medicine (Malden, MA), 2017-11, Vol.6 (11), p.2732-2744

2017

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Aktive Filter

ThemaBreast Neoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(56)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(57)
Female
(54)
Science & Technology
(51)
Life Sciences & Biomedicine
(49)
Oncology
(41)
Breast Cancer
(31)
Middle Aged
(26)
Aged
(24)
Breast Neoplasms - Pathology
(24)
Adult
(23)
Trastuzumab
(19)
Chemotherapy
(16)
Treatment Outcome
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Cancer
(14)
Chemotherapy, Adjuvant
(14)
Hematology, Oncology And Palliative Medicine
(14)
Antineoplastic Agents - Therapeutic Use
(13)
Aged, 80 And Over
(12)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies

Pertuzumab and trastuzumab: the rationale way to synergy

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

Looking for predictive markers in breast cancer – Authors' reply

Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBC

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Simultaneous quantification of four hormone therapy drugs by LC-MS/MS: Clinical applications in breast cancer patients

Does Concurrent Radiochemotherapy Affect Cosmetic Results in the Adjuvant Setting After Breast-Conserving Surgery? Results of the ARCOSEIN Multicenter, Phase III Study: Patients’ and Doctors’ Views

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer

Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective

Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer

High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First‐Line Treatment for HER‐2‐positive Locally Recurrent or Metastatic Breast Cancer

Prospective Clinical Utility Study of the Use of the 21‐Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor‐Positive Early Invasive Breast Cancer: Results From the SWITCH Study

The emerging role of aromatase inhibitors in the adjuvant management of breast cancer

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial

Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic

Concurrent trastuzumab – Internal mammary irradiation for HER2 positive breast cancer: “It hurts to be on the cutting edge”

Incidence, risk factors, and outcomes of central venous catheter‐related thromboembolism in breast cancer patients: the CAVECCAS study

Aktive Filter

Suchergebnisse filtern